Udo Johannes Vetter
Direktor/Vorstandsmitglied bei GLAND PHARMA LIMITED
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Srinivas Sadu | M | 55 | 24 Jahre | |
Axel Herberg | M | 66 |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | 10 Jahre |
Oliver Buck | M | - |
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011.
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
International Centers for Precision Oncology Foundation
| 19 Jahre |
Pallerlamudi Sampath Kumar | M | - | 14 Jahre | |
Michael Lee-Chin | M | 73 |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011.
International Centers for Precision Oncology Foundation
| 5 Jahre |
Gunther Strothe | M | - |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
RV Invest GmbH
RV Invest GmbH Investment ManagersFinance RV Invest GmbH provides business and economic services. The private company is based in Ravensburg, Germany. The CEOs are Udo Johannes Vetter, Gunther Strothe, Wolfgang Kerkhoff. The German company was founded in 2016.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011. | 8 Jahre |
Annette Koehler | M | 57 | 2 Jahre | |
Shilpi Sahay | M | - | 10 Jahre | |
Manuel Salvisberg | M | - |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011. | - |
Essaji Goolam Vahanvati | M | - | 4 Jahre | |
Paul Schilling | M | 54 | 7 Jahre | |
Katja Mögel-Schnitzler | F | 43 | 8 Jahre | |
C. S. Venkatesan | M | - | 26 Jahre | |
Andrea Abt | F | 64 | 9 Jahre | |
Markus Rocholz | M | 54 | 12 Jahre | |
Satyanaraynna Murthy Chavali | M | 57 | 6 Jahre | |
Surapanini Sridevi | M | - | 22 Jahre | |
Ashish Adhikari | M | - | 5 Jahre | |
Naina Lal Kidwai | F | 67 | 3 Jahre | |
Robert Froehler | M | 64 | 2 Jahre | |
Francesco Grioli | M | 52 | 13 Jahre | |
Marlis Mergenthal | F | 38 | 2 Jahre | |
Qi Yu Chen | M | 52 | 7 Jahre | |
Steffen Schuster | M | 59 |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011. | 13 Jahre |
Ueli Utzinger | M | - | 3 Jahre | |
Fang Yao | M | 54 | 2 Jahre | |
Nicholas H. Vetter | M | - |
OncoBeta GmbH
OncoBeta GmbH Medical SpecialtiesHealth Technology OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown. | - |
Shannon D. Brown | M | - |
OncoBeta GmbH
OncoBeta GmbH Medical SpecialtiesHealth Technology OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown. | - |
Rong Wu | M | - | - | |
Richard P. Baum | M | - |
International Centers for Precision Oncology Foundation
| - |
Taranjit Singh | M | - |
International Centers for Precision Oncology Foundation
| - |
Odile Jaume | F | - |
International Centers for Precision Oncology Foundation
| - |
Jia Ai Zhang | M | - | 3 Jahre | |
Sumanta Bajpayee | M | - | 4 Jahre | |
Ravi Shekhar Mitra | M | - | 5 Jahre | |
Wolfgang Kerkhoff | M | - |
RV Invest GmbH
RV Invest GmbH Investment ManagersFinance RV Invest GmbH provides business and economic services. The private company is based in Ravensburg, Germany. The CEOs are Udo Johannes Vetter, Gunther Strothe, Wolfgang Kerkhoff. The German company was founded in 2016. | 6 Jahre |
Lukas Burkhardt | M | 45 | 6 Jahre | |
Bent Reichardt | M | - |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany. | - |
Martin Bosch | M | - |
International Centers for Precision Oncology Foundation
| - |
Marion Stolzenwald | F | 64 | 13 Jahre | |
Dietmar Siemssen | M | 61 | 6 Jahre | |
Stefan Sanktjohanser | M | - |
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011. | 4 Jahre |
Tadd Seaton Wessel | M | - |
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011. | 3 Jahre |
Oskar Gold | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | - |
Hermann Piana | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | 20 Jahre |
Joachim del Boca | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | - |
Peter Sölkner | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | 16 Jahre |
Bernd Metzner | M | 53 | 5 Jahre | |
Thomas Otto | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | 29 Jahre |
Manish Bharadwaj | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Deutschland | 63 | 72,41% |
Indien | 24 | 27,59% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Udo Johannes Vetter
- Persönliches Netzwerk